Welcome to our dedicated page for Misonix news (Ticker: MSON), a resource for investors and traders seeking the latest updates and insights on Misonix stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Misonix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Misonix's position in the market.
Misonix reported its fiscal 2021 second-quarter results, revealing a revenue decline of 7.4% year-over-year to $18.3 million, impacted by COVID-19. Domestic surgical revenue grew by 19.8%, while international revenue dropped by 23.1%. Gross profit margin improved to 71.2%. The net loss narrowed to $1.3 million, from $5.1 million in the same quarter last year. Adjusted EBITDA turned positive at $1.6 million. The company aims to enhance its market position and is optimistic about recovery in procedural volumes following vaccine distribution.
Misonix, Inc. (NASDAQ: MSON) has announced that it will report its fiscal 2021 second-quarter financial results on February 4, 2021, after market close. The company will hold a conference call and webcast at 4:30 p.m. ET to discuss these results, which is open to the public. Interested parties can access the call by dialing 866-248-8441 domestically, or 323-289-6576 internationally, using conference ID 2793331. A replay of the webcast will be available for 30 days on Misonix's website.
Misonix, Inc. (Nasdaq: MSON) announced its participation in the 39th Annual J.P. Morgan Healthcare Conference. CEO Stavros Vizirgianakis and CFO Joe Dwyer will present virtually on January 14th at 3:40 p.m. ET. The management team will also engage in one-on-one meetings with institutional investors throughout the day. A live webcast of the presentation will be available on the company's website. Misonix specializes in minimally invasive ultrasonic medical devices and regenerative products aimed at improving clinical outcomes.
Misonix, Inc. (NASDAQ: MSON) has announced that the second largest U.S. commercial payer will cover TheraSkin for all lower extremity dermal wounds. This coverage decision potentially increases patient access to TheraSkin, as it adds 32 million covered lives. TheraSkin is a cellular and tissue-based treatment that has shown significant benefits in healing chronic wounds, with over 100,000 applications. CEO Stavros Vizirgianakis highlighted this as a major step in establishing TheraSkin as a standard care option, backed by strong clinical evidence and positive healthcare practitioner feedback.
Misonix, Inc. (NASDAQ: MSON) announced participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 2 and 3, 2020. CEO Stavros Vizirgianakis and CFO Joe Dwyer will engage in one-on-one meetings with registered investors during the event. Misonix specializes in minimally invasive ultrasonic medical devices and regenerative products that enhance clinical results. Their offerings include products for surgery and wound care, aimed at improving outcomes in various medical fields.
Misonix, Inc. (NASDAQ: MSON) announced its participation in the Craig-Hallum 11th Annual Alpha Select Conference and the Canaccord Genuity Virtual MedTech & Diagnostics Forum in November 2020. CEO Stavros Vizirgianakis and CFO Joe Dwyer will host one-on-one meetings with investors at these events. The Craig-Hallum conference is set for November 17, 2020, while the Canaccord Genuity forum will occur on November 19, 2020. Misonix specializes in minimally invasive ultrasonic medical devices and regenerative products that enhance clinical outcomes.
Misonix, Inc. (MSON) reported its fiscal 2021 first quarter results, revealing a revenue increase of 59.1% to $17.7 million compared to $11.1 million for the same period last year. Despite the growth, the company incurred a net loss of $5.0 million, down from a profit of $1.8 million in fiscal 2020. Operating expenses rose by $6.5 million due to the acquisition of Solsys Medical. Adjusted EBITDA showed a loss of $2.2 million. Domestic surgical revenue increased by 21.5%, while international revenue decreased by 35% due to COVID-19 impacts.
Misonix, Inc. (NASDAQ: MSON) will announce its fiscal 2021 first-quarter financial results on November 5, 2020, after market close. The preliminary revenue for this quarter is approximately $17.7 million. The company currently holds around $35 million in cash and cash equivalents as of September 30, 2020. A conference call will take place at 4:30 p.m. ET on the same day for public review of the results, accessible via dial-in or webcast on Misonix’s investor relations page.
Misonix, Inc. (Nasdaq: MSON) reported preliminary revenue of approximately $17.7 million for the first quarter of fiscal 2021, up from $11.1 million year-over-year. This growth is attributed to over 20% increase in domestic surgical revenue, despite a 13% decline in domestic wound revenue. The company expects further opportunities for growth through new products and distribution agreements. Cash and equivalents at quarter-end stood at $35 million. Full results will be announced in early November 2020.
Misonix, Inc. (MSON) announced an exclusive agreement with Gunze Limited for the supply and distribution of its TheraGenesis® Bilayer Wound Matrix in the U.S. TheraGenesis, an FDA-cleared collagen wound matrix, is designed for treating trauma, burn, and reconstructive wounds. This partnership aims to enhance Misonix's position in the over $1 billion U.S. skin substitute market, complementing its existing product offerings. Misonix’s CEO highlighted the potential for market share growth, leveraging Gunze’s success in international markets.
